Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896568 · ClinicalTrials.gov registry record · Phase 1
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
A Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT03896568 is a Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03896568, a Phase 1 study of Recurrent Glioblastoma and Recurrent Malignant Glioma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
Conditions Studied
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- BIOLOGICAL Oncolytic Adenovirus Ad5-DNX-2401
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896568
The ClinicalTrials.gov registry entry for NCT03896568 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (47% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT03896568 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03896568 about?
NCT03896568 is a clinical study titled "MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma". This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause ...
What is the current status of trial NCT03896568?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2019-02-12. Estimated completion is 2027-09-30.
What conditions does trial NCT03896568 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Gliosarcoma, Recurrent Anaplastic Astrocytoma, IDH1 wt Allele.
What interventions are being tested in trial NCT03896568?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), Oncolytic Adenovirus Ad5-DNX-2401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03896568?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03896568 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.